메뉴 건너뛰기




Volumn 22, Issue 8, 2011, Pages 794-800

Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction

Author keywords

bevacizumab; everolimus; kidney cancer; renal dysfunction; sunitinib; temsirolimus

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

EID: 80051537982     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328346af0d     Document Type: Article
Times cited : (26)

References (30)
  • 2
    • 33744958838 scopus 로고    scopus 로고
    • Long-term outcomes of the surgical management of renal cell carcinoma
    • DOI 10.1007/s00345-006-0055-5
    • Lam JS, Belldegrun AS, Pantuck AJ. Long-term outcomes of the surgical management of renal cell carcinoma. World J Urol 2006; 24:255-266. (Pubitemid 44138180)
    • (2006) World Journal of Urology , vol.24 , Issue.3 , pp. 255-266
    • Lam, J.S.1    Belldegrun, A.S.2    Pantuck, A.J.3
  • 7
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3    Hutson, T.E.4    Porta, C.5    Bracarda, S.6
  • 9
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3    Szczylik, C.4    Lee, E.5    Wagstaff, J.6
  • 10
    • 70449379934 scopus 로고    scopus 로고
    • Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function
    • Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer 2009; 7:E10-E15.
    • (2009) Clin Genitourin Cancer , vol.7
    • Parsa, V.1    Heilbrun, L.2    Smith, D.3    Sethi, A.4    Vaishampayan, U.5
  • 12
    • 65249140620 scopus 로고    scopus 로고
    • A phase i mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects
    • Abstract 9072 Los Angeles California USA: AACR;
    • Bello CL, Patyna S, Kang P, Klamerus K. A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects. In: Annual Meeting of the American Association for Cancer Research. Los Angeles, California, USA: AACR; 2007. Abstract 9072.
    • (2007) Annual Meeting of the American Association for Cancer Research
    • Bello, C.L.1    Patyna, S.2    Kang, P.3    Klamerus, K.4
  • 14
    • 80051509196 scopus 로고    scopus 로고
    • Wyeth Pharmaceuticals Inc. Rev September of 22
    • Temsirolimus prescribing information booklet. Wyeth Pharmaceuticals Inc. Rev September 2010; page 17 of 22.
    • (2010) Temsirolimus Prescribing Information Booklet , pp. 17
  • 15
    • 34548787904 scopus 로고    scopus 로고
    • Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study
    • DOI 10.1002/cncr.22904
    • Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376-1384. (Pubitemid 47435612)
    • (2007) Cancer , vol.110 , Issue.6 , pp. 1376-1384
    • Launay-Vacher, V.1    Oudard, S.2    Janus, N.3    Gligorov, J.4    Pourrat, X.5    Rixe, O.6    Morere, J.-F.7    Beuzeboc, P.8    Deray, G.9
  • 18
    • 70349233039 scopus 로고    scopus 로고
    • Sunitinib treatment in patients with severe renal function impairment: A report of four cases by the hellenic cooperative oncology group
    • Lainakis G, Bamias A, Psimenou E, Fountzilas G, Dimopoulos MA. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the hellenic cooperative oncology group. Clin Nephrol 2009; 72:73-78.
    • (2009) Clin Nephrol , vol.72 , pp. 73-78
    • Lainakis, G.1    Bamias, A.2    Psimenou, E.3    Fountzilas, G.4    Ma, D.5
  • 19
    • 49849101828 scopus 로고    scopus 로고
    • Sorafenib: Tolerance in patients on chronic hemodialysis: A single-center experience
    • Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 2008; 74:245-246.
    • (2008) Oncology , vol.74 , pp. 245-246
    • Rey, P.M.1    Villavicencio, H.2
  • 20
    • 34147205677 scopus 로고    scopus 로고
    • Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values
    • DOI 10.1373/clinchem.2006.077180
    • Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53:766-772. (Pubitemid 46580250)
    • (2007) Clinical Chemistry , vol.53 , Issue.4 , pp. 766-772
    • Levey, A.S.1    Coresh, J.2    Greene, T.3    Marsh, J.4    Stevens, L.A.5    Kusek, J.W.6    Van Lente, F.7
  • 22
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer Eawanders, J.3    Kaplan, R.S.4    Rubinstein, L.5
  • 24
    • 77954843443 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function
    • Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010; 50:472-481.
    • (2010) J Clin Pharmacol , vol.50 , pp. 472-481
    • Khosravan, R.1    Toh, M.2    Garrett, M.3    La Fargue, J.4    Ni, G.5    Marbury, T.C.6
  • 25
    • 84888443122 scopus 로고    scopus 로고
    • Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis 2009
    • Orlando, FL 2009. p. J Clin Oncol (Supplement; abstr 5109)
    • Josephs D, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. In: 2009. ASCO Annual Meeting. Orlando, FL 2009. p. J Clin Oncol 27:15 s (Supplement; abstr 5109).
    • ASCO Annual Meeting , vol.27
    • Josephs, D.1    Hutson, T.E.2    Pickering, L.M.3    Larkin, J.M.4    Choueiri, T.K.5    Patel, T.V.6
  • 26
    • 55049136730 scopus 로고    scopus 로고
    • Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies
    • Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13:1084-1096.
    • (2008) Oncologist , vol.13 , pp. 1084-1096
    • Hutson, T.E.1    Figlin, R.A.2    Kuhn, J.G.3    Motzer, R.J.4
  • 27
    • 38549156660 scopus 로고    scopus 로고
    • Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure [2]
    • DOI 10.1159/000112828
    • Inauen R, Cathomas R, Boehm T, Koeberle D, Pestalozzi BC, Gillessen S, et al. Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 2007; 72:209-210. (Pubitemid 351161612)
    • (2007) Oncology , vol.72 , Issue.3-4 , pp. 209-210
    • Inauen, R.1    Cathomas, R.2    Boehm, T.3    Koeberle, D.4    Pestalozzi, B.C.5    Gillessen, S.6    Von Moos, R.7
  • 29
    • 77950952997 scopus 로고    scopus 로고
    • Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial
    • Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010; 89:864-872.
    • (2010) Transplantation , vol.89 , pp. 864-872
    • Gullestad, L.1    Iversen, M.2    Mortensen, S.A.3    Eiskjaer, H.4    Riise, G.C.5    Mared, L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.